Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
alkivia+ long-term extension in idiopathic inflammatory myopathy
jRCT2031240524Phase 3Recruiting
- Sponsor
- argenx
- Start
- Jun 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in Autoimmune Myopathies, sponsored by argenx. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Incidence and severity of adverse events of special interest and 4 more. Started Jun 2025; status: recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on jRCT2031240524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240524.